Matt Chu Email & Phone Number

• Built the Protein Engineering function enabling Design-Discovery-Production-Analysis capabilities to lead/support Cancer Cell Therapy & Tumor Microenvironment programs• Fostered collaboration with a number of Astellas groups including the Tsukuba Biologics Engineering, Pharmaceutical Science & Technology Labs, Astellas Gene Therapy, Advanced Informatics & Analytics, as well as the Functional Chapters in AI Drug-Discovery and Biologics Research• As a member of the Xyphos leadership team, helping shape both the science and culture on site in South San FranciscoMore update soon:https://xyphosinc.com/company/management-team/

South San Francisco, Ca, Us

Group leader of the Protein Sciences Team to oversee protein/antibody-related activities• Managing 3 direct reports and CROs to support antigen/antibody production and analytics/characterization• Leading new target identification and validation; champion of an exploratory immunomodulator project• Supporting CMC activities for development and manufacture of two clinical drugs (TTX-030 and -080), and IND filing• Other responsibility: Member of senior management team to support the leadership team

South San Francisco, Ca, Us

Head of Protein Sciences

New York, New York, Us

Co-Research Project Lead for a newly initiated program to target cancer immunosuppression• Worked closely with biology lead to define project strategy, surveyed competitive landscape / IP profiles, drafted work plan and timeline, and presented to leadership team• Managed a direct report to design various bispecific and multivalent cell-type specific targeting antibodies for programs• Other responsibilities: First- and co-authored two submitted publications for the studies of cytokine therapeutics and bispecific T-cell engager in different formats, respectively

New York, New York, Us

Protein Engineering Lead to advance the top-priority targeted-cytokine program from lead selection to pre-IND• Designed and engineered novel, targeted antibody-cytokine fusion variants through structure-based and saturation mutagenesis approaches; Delivered >100 constructs for lead selection under a tight timeline• Developed scalable purification process to generate challenging antigens and antibody-cytokine proteins in high quality and high yield for pre-clinical studies• Analyzed and presented biophysical, biosensor, in vitro / in vivo and structural data with project teams to facilitate the iterative process for lead optimization and engineering• Managed collaboration and represented the site to provide project updates to the process development team to facilitate manufacture of the lead molecule• Other responsibilities: Started a cytokine-receptor project as a postdoc-mentorship research proposal; Managed five Äkta Avant systems and provided training for the site; Co-authored of an anti-OX40 antibody paper

GPCR crystallographer and Principal Investigator for a Phase I / Phase II SBIR grant awarded project• GPCR engineering and crystallography lead: Managed and oversaw all crystallography-related activities• Developed purification strategies using different detergents and lipids to prepare stable GPCR–G-protein/nanobody complexes for crystallography and cryo-EM studies, and contributed to two publications in Nature• Leading author of a Small Business Innovation Research (SBIR) proposal, awarded a $1.3M 3-year Phase I/II grant• Solved two crystal structures of Family A GPCRs to trigger milestone payments in the collaboration with UCB (Press Release in February 2016; publication submitted in 2020), and published one of the structures in PNAS

Palo Alto, Ca, Us

Advisor: Prof. William I. WeisDesigned, executed and published research on the molecular basis of Wnt–receptor interaction and signaling• Optimized the expression and purification for various challenging Wnt signaling components (Extracellular ligands: Wnt, Dkk1, Norrin; Receptors: Frizzled, LRP6; Intracellular signaling molecules: Dvl, Axin, GSK-3, CK1)• Devised biophysical and structural approaches to demonstrate the ligand-induced conformation change of LRP6, and uncover the spatial relationship of its large ectodomain to Wnts, Dkk1 and Frizzled for signaling• Developed a quantitative Native PAGE mobility shift assay for the analysis of LRP6–Wnt, LRP6–DKK1 and LRP6–Fab protein complex formation using fluorescent-dye conjugated antibodies• Crystallized and solved the first apo structure of a Wnt ligand, subsequently identified a LRP6-binding site• Determined five crystal structures of Axin-bound GSK-3 kinase in complex with peptides derived from the LRP6 inhibitory motifs, and revealed a substrate binding pocket for the design of more selective inhibitors against GSK-3• Mentored 1 junior postdoctoral fellow on a new project extended from my previous findings

Ph.D., Pharmacy And Pharmaceutical Sciences (Biochemistry & Structural Biology)

Master Of Philosophy - Mphil, Molecular Biotechnology

Bachelor Of Science - Bs, Biochemistry